HC Wainwright Reaffirms “Buy” Rating for Replimune Group (NASDAQ:REPL)

Replimune Group (NASDAQ:REPL)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $22.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 132.80% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Piper Sandler upped their price target on Replimune Group from $14.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, June 2nd. Cantor Fitzgerald started coverage on Replimune Group in a report on Friday, June 20th. They issued an “overweight” rating for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $20.83.

Replimune Group Stock Down 1.0%

REPL stock opened at $9.45 on Thursday. The firm’s fifty day simple moving average is $9.05 and its 200-day simple moving average is $10.57. The company has a market capitalization of $728.50 million, a P/E ratio of -3.08 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.95 and a quick ratio of 7.95. Replimune Group has a 12 month low of $6.44 and a 12 month high of $17.00.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the firm earned ($0.25) EPS. As a group, equities research analysts forecast that Replimune Group will post -2.97 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In other news, Director Philip Astley-Sparke sold 32,279 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $260,168.74. Following the completion of the sale, the director directly owned 1,405,071 shares in the company, valued at $11,324,872.26. This represents a 2.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Sushil Patel sold 25,105 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total transaction of $202,346.30. Following the completion of the sale, the chief executive officer owned 343,576 shares of the company’s stock, valued at $2,769,222.56. This trade represents a 6.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 74,907 shares of company stock valued at $603,655. Insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its position in shares of Replimune Group by 42.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 778,163 shares of the company’s stock valued at $9,425,000 after buying an additional 232,822 shares during the last quarter. Nuveen Asset Management LLC increased its position in Replimune Group by 108.9% during the fourth quarter. Nuveen Asset Management LLC now owns 667,634 shares of the company’s stock worth $8,085,000 after purchasing an additional 347,993 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in Replimune Group during the fourth quarter worth about $543,000. GAMMA Investing LLC increased its position in Replimune Group by 897.2% during the first quarter. GAMMA Investing LLC now owns 8,795 shares of the company’s stock worth $902,000 after purchasing an additional 7,913 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after purchasing an additional 5,922 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.